ArdorComm Media Group

Tuesday, November 17, 2026 6:47 AM

Public Health

India Records 38% Decline in TB Mortality Since 2015, WHO Report Shows

India has recorded a 38 per cent decline in tuberculosis (TB)-related deaths since 2015, surpassing the global reduction of 35 per cent, according to the World Health Organization’s (WHO) Global Tuberculosis Report 2026. The country has also achieved a 94 per cent treatment success rate among patients with drug-susceptible TB. The report highlights that the South-East Asia Region accounted for the largest share of new TB cases globally in 2025, at 35 per cent, followed by the Western Pacific Region at 27 per cent and the African Region at 25 per cent. Around 88 per cent of newly reported TB cases were concentrated in 30 countries. India alone contributed approximately a quarter of the global burden, followed by Indonesia (10 per cent), the Philippines (6.8 per cent), China (6.5 per cent), Pakistan (6.4 per cent), Nigeria (4.9 per cent), the Democratic Republic of the Congo (3.9 per cent) and Bangladesh (3.7 per cent). The five countries with the highest burden collectively accounted for 55 per cent of global cases. Globally, TB continues to impose a significant financial burden on affected households. Nearly half of people receiving TB treatment and their families face catastrophic expenses, exceeding 20 per cent of their total household income, when medical and non-medical costs and income losses are taken into account. The report also identifies several factors that increase the risk of developing TB, including HIV infection, undernutrition, diabetes and tobacco use. An estimated 9.6 lakh new cases were linked to undernutrition, 9.2 lakh to diabetes, 7.3 lakh to alcohol use disorders, 6.9 lakh to smoking and 5.5 lakh to HIV infection. Worldwide, approximately 10.6 million people developed TB in 2025, including 5.7 million men, 3.7 million women and 1.2 million children. The disease claimed an estimated 1.13 million lives during the year, remaining the world’s leading cause of death from a single infectious agent. Drug-resistant tuberculosis, particularly multidrug-resistant TB (MDR-TB), continues to pose a serious public health and health security challenge. Only around two in five people diagnosed with drug-resistant TB received treatment in 2025. However, global interventions against the disease have helped save an estimated 86 million lives since 2000. In India, the TB Mukt Bharat Abhiyaan has expanded screening efforts significantly. Between December 7, 2024, and November 8, 2026, the campaign brought more than 25 crore individuals within the ambit of TB screening activities. According to the Union Health Ministry, the decline in TB mortality has been driven by interventions under the National TB Elimination Programme (NTEP). These include active case detection using AI-enabled X-rays, rapid diagnostic services, timely treatment initiation, differentiated care and nutritional assistance through the Nikshay Poshan Yojana and Nikshay Mitra initiative. The ministry also highlighted the use of artificial intelligence tools to identify disease hotspots, predict high-risk patients likely to experience adverse outcomes and support patient engagement through Khushi, an AI-powered chatbot and avatar-based videobot. Tuberculosis is a bacterial infectious disease that primarily affects the lungs and spreads through the air when an infected person coughs, sneezes or spits. Despite its continued global impact, the disease is both preventable and curable. Source: The Hindu  

India Records 38% Decline in TB Mortality Since 2015, WHO Report Shows Read More »

India needs specific PM2.5 reduction targets to combat air pollution: FICCI-EY report

India must adopt a health-focused strategy to tackle air pollution, with clearly defined targets for reducing fine particulate matter (PM2.5) under the National Clean Air Programme (NCAP), according to a new knowledge paper by FICCI and EY titled “Clean Air, Healthy India.” The report highlights the serious public health consequences of air pollution, noting that more than two million deaths in India were attributed to pollution in 2023. It identifies PM2.5 particles, which measure 2.5 microns or less, as a major health concern because they can penetrate deep into the lungs and enter the bloodstream. Long-term exposure to these pollutants is linked to respiratory diseases, cardiovascular conditions, strokes and cognitive impairment. The resulting health burden also increases healthcare costs and affects workforce productivity. Dr. Ashutosh Raghuvanshi, Chair of the FICCI Health Services Committee and MD and CEO of Fortis Healthcare, emphasised that clean air should be treated as a central public health priority rather than solely an environmental concern. He highlighted the role of healthcare institutions in raising public awareness, monitoring pollution-related illnesses and improving healthcare preparedness. He also called for stronger cooperation among government, industry and healthcare providers to achieve measurable health improvements. Similarly, Dr. Arun Agarwal, Chair of the FICCI Working Group on Air Pollution (Healthcare Perspective), former Dean of MAMC and Medical Advisor to Apollo Hospitals Group, stressed the need to move beyond seasonal measures and make pollution exposure reduction a year-round public health priority. He underlined the importance of integrating air-quality monitoring with health surveillance, strengthening preventive measures and developing interventions based on local pollution sources. Ahead of the peak pollution season, FICCI-EY has called for immediate action and outlined 10 practical recommendations to address major sources of emissions. Among the proposed measures is the introduction of closed-loop dust management systems at large construction sites to control construction and demolition pollution. The report also recommends identifying pollution hotspots associated with traffic, industrial activity, construction and waste burning, followed by testing targeted interventions. To reduce vehicular emissions, the paper suggests deploying smart traffic signals to minimise congestion, vehicle idling and stop-start traffic. For industrial and backup-power pollution, it recommends using real-time stack-emission data to strengthen industrial pollution management, upgrading conventional brick kilns to zigzag firing technology and replacing diesel-based backup power systems with battery-hybrid alternatives. The report further advocates technology-driven solutions to monitor and control industrial emissions, diesel soot and pollution in areas with high human exposure. Addressing agricultural and waste-related pollution, the recommendations include converting crop residue into fuel and commercially viable products to reduce stubble burning. It also proposes using recovered plastic, industrial waste and construction and demolition debris in building houses and infrastructure. The FICCI-EY paper emphasises that effective implementation will require clear government standards and consistent regulatory frameworks. It calls on industries to prioritise efficiency, competitiveness and innovation, while healthcare institutions strengthen health surveillance and public advisories. The report also highlights the importance of community participation, stressing that people must have access to reliable information and opportunities to contribute to local clean-air initiatives. Source: Economic Times

India needs specific PM2.5 reduction targets to combat air pollution: FICCI-EY report Read More »

Government proposes immediate suspension of manufacturing licences for substandard drugs

The Union Health Ministry has proposed changes to the Drugs Rules, 1945, that would allow authorities to immediately suspend the manufacturing licences of pharmaceutical companies producing medicines that fail to meet specified critical quality standards. The proposed amendments, announced on November 4, 2026, aim to strengthen drug quality monitoring, enable faster regulatory action against substandard medicines and prevent potentially unsafe products from remaining in circulation. Under the existing rules, suspension or cancellation of a drug manufacturing licence generally involves a prescribed regulatory process, including the issuance of a show-cause notice. This can create a delay between the identification of a Not of Standard Quality (NSQ) drug and the initiation of action, during which the medicine may continue to be available in the market. To address this gap, the ministry has proposed empowering the Central Licensing Approving Authority or the concerned State Licensing Authority to immediately suspend a drug’s manufacturing licence after receiving a Government Analyst’s report declaring it NSQ on specified parameters. These include assay, dissolution, related substances, impurities and sterility. According to the ministry, failures involving these parameters can directly affect medicine quality and patient safety, requiring immediate regulatory intervention. Manufacturers must implement corrective measures The proposed framework also specifies conditions for revoking a suspension. Manufacturers will be required to conduct a comprehensive root cause analysis to identify the reasons behind the quality failure and implement appropriate Corrective and Preventive Action (CAPA). The suspension will remain in force until the licensing authority is satisfied that the necessary corrective measures have been implemented and verified. This is intended to ensure that quality deficiencies are properly addressed and measures are taken to prevent similar failures in the future. The ministry has also proposed changes to Form 13, which covers Government Analyst test reports, to improve communication and coordination among regulatory authorities and industry stakeholders. Under the revised mechanism, copies of NSQ reports will be sent to the Drugs Controller General of India (DCGI), the relevant State or Union Territory Licensing Authority overseeing the manufacturing facility, and the manufacturer and marketer of the concerned medicine. The government said the arrangement would facilitate faster information sharing, coordinated regulatory action and greater accountability across the pharmaceutical manufacturing and distribution chain. Draft amendments open for public consultation The proposed changes follow discussions at the 65th meeting of the Drugs Consultative Committee held on December 20, 2024, and recommendations made during the 92nd meeting of the Drugs Technical Advisory Board on April 24, 2025. The amendments are expected to improve post-marketing drug surveillance, strengthen action against manufacturers of substandard medicines and enhance accountability among pharmaceutical companies and marketers. The draft rules have been released for public consultation. Stakeholders and members of the public can submit their objections and suggestions within 30 days from the date on which the relevant Gazette of India notification becomes available. Source: The Hindu

Government proposes immediate suspension of manufacturing licences for substandard drugs Read More »

WHO Advises Against Obesity Drugs and Surgery for Children Under 10

The World Health Organization (WHO) has issued its first guidelines focused specifically on tackling obesity among children and adolescents, recommending lifestyle-based interventions rather than medicines or surgery for children under the age of 10. The global health agency said children aged 0 to 9 should not be treated with weight-loss medicines, bariatric surgery or weight-loss devices. Instead, it strongly recommends comprehensive programmes centred on healthy diets, regular physical activity and sustainable behavioural changes. For adolescents aged 10 to 19, approved obesity medicines may be considered in selected cases when supervised lifestyle programmes have failed to produce the desired results. Bariatric surgery may also be considered for adolescents with severe obesity, but only under strict conditions and appropriate medical supervision. The recommendations differ from WHO’s guidance for adults, which has recognised the potential role of newer weight-management medicines, including GLP-1 receptor agonists, in treating obesity. The scale of childhood obesity has become a growing global concern. WHO estimates that around 70 million children aged five to nine and approximately 100 million adolescents aged 10 to 19 were living with obesity in 2024. Among people aged five to 19, the global prevalence of obesity increased from about 2 per cent in 1990 to 8 per cent in 2024. WHO officials said the increase is being seen across regions, including low- and middle-income countries. The agency emphasised that the foundation of obesity care for young people should be access to nutritious food, physical activity and sustained support for healthier behaviours. The guidelines also highlight the importance of mental health. Anxiety, depression and low self-esteem can influence eating habits, physical activity and social behaviour. At the same time, children and adolescents living with obesity may face stigma, discrimination and bullying. WHO experts noted that bariatric surgery could be considered for some adolescents with severe obesity and related complications, such as type 2 diabetes or hypertension, particularly when lifestyle interventions have not been effective. Such cases require careful assessment and specialised medical supervision. Source: AFP Photo Credit: Reuters

WHO Advises Against Obesity Drugs and Surgery for Children Under 10 Read More »

Every Additional 100 Grams of Ultra-Processed Food Linked to Higher Heart Disease Risk: Study

Higher consumption of ultra-processed foods (UPFs) has been associated with increased risks of several chronic health conditions, including cardiovascular disease, cancer, obesity and metabolic disorders, according to a study. The research found that greater intake of ultra-processed foods was associated with a 24 per cent higher risk of cardiovascular events, a 12 per cent higher risk of cancer and a 23 per cent higher risk of overweight or obesity. Higher consumption was also linked with increased risks of metabolic syndrome or diabetes, depression and anxiety, digestive diseases, high blood pressure and death from any cause. Ultra-processed foods are industrially manufactured products that are typically ready to eat or require minimal preparation. They often contain high levels of energy, sugar and salt while providing relatively low amounts of dietary fibre, protein, vitamins and minerals. The researchers found a dose-response relationship between UPF consumption and several health outcomes. Every additional 100 grams of ultra-processed food consumed per day was associated with an 11 per cent higher risk of hypertension, a 14 per cent higher risk of cardiovascular events, a 4 per cent higher risk of cancer and a 3 per cent higher risk of death from any cause. The study also reported that every 10 per cent increase in the share of energy intake coming from ultra-processed foods was associated with a 16 per cent higher risk of metabolic syndrome or diabetes. Researchers suggested that the potential health effects could be linked to several factors. Emerging evidence indicates that combinations of food additives may have cumulative effects, while extensive industrial processing can alter the physical structure of food and potentially affect the gut microbiome. These changes may contribute to inflammation and insulin resistance. The researchers also pointed to compounds that can form during food processing. Acrylamide, which can develop in certain foods during high-temperature processing, and acrolein, which can be generated when fats are heated, have both been associated with cardiovascular health risks. The authors noted that chronic conditions associated with high UPF consumption can occur together as multimorbidity. They suggested that reducing ultra-processed food intake and replacing such products with minimally processed alternatives could be relevant to chronic disease prevention and primary healthcare. Source: PTI

Every Additional 100 Grams of Ultra-Processed Food Linked to Higher Heart Disease Risk: Study Read More »

India Could Get Indigenous Dengue Vaccine by End of 2027: ICMR DG

India could have its own indigenous dengue vaccine by the end of next year, provided the ongoing follow-up of participants in the vaccine’s Phase 3 clinical trial progresses as expected, ICMR Director General Rajiv Bahl said. Speaking in Kolkata on Sunday, Bahl said the randomised Phase 3 trial is being conducted across 20 institutes and involves more than 13,000 volunteers. For every two participants who received the vaccine, one was administered a placebo. Nearly a year of follow-up has been completed, and researchers are hopeful of unblinding the trial results by the end of next year. NIRBI Director Santasabuj Das said the institute, formerly known as NICED, is among the centres participating in the nationwide trial and is monitoring 674 enrolled volunteers. DengiAll, described as India’s first indigenous single-dose dengue vaccine, is designed to provide protection against all four dengue virus serotypes circulating in the country. However, relatively low dengue transmission this year could delay the process of obtaining enough data to unblind the trial. Bahl also highlighted the importance of Kangaroo Mother Care (KMC) during the fourth Dilip Mahalanabis Oration organised by the Liver Foundation West Bengal. KMC involves prolonged skin-to-skin contact between a newborn and the mother and has been shown to improve outcomes for vulnerable newborns. Reflecting on the legacy of late public health pioneer Dilip Mahalanabis, Bahl highlighted the development of sick newborn care units and the evolution of the model into Mother Newborn Care Units, which promote zero separation between mothers and preterm or sick newborns. Public health activist and hepatologist Abhijit Chowdhury said Mahalanabis demonstrated how simple, evidence-based healthcare interventions can have a transformative impact on human lives, inspiring the foundation to organise an annual oration in his memory. Source: Economic Times

India Could Get Indigenous Dengue Vaccine by End of 2027: ICMR DG Read More »

Jharkhand on high alert over H1N1 as Health Minister orders hospitals to reserve beds, intensify surveillance

The Jharkhand Health Department has stepped up preparedness across the state amid concerns over potential H1N1, or swine flu, cases, with Health Minister Irfan Ansari directing officials to strengthen surveillance, testing and hospital readiness. Ansari chaired a high-level review meeting with senior health officials, medical college authorities and district Civil Surgeons, directing surveillance teams to closely monitor suspected cases and ensure their prompt reporting. Assuring residents that there was no need to panic, the Health Minister said H1N1 is a respiratory viral infection and that most patients recover with timely diagnosis and appropriate treatment. He urged people to seek medical attention promptly if they develop symptoms. As part of the preparedness measures, authorities have been asked to reserve 10 additional beds at every medical college hospital, including Rajendra Institute of Medical Sciences (RIMS) in Ranchi, as well as at all district Sadar Hospitals. Hospitals have also been instructed to maintain sufficient stocks of medical oxygen and essential medicines, strengthen diagnostic facilities and ensure ICU and HDU readiness. Adequate trained medical and paramedical staff are also to be kept available to handle any surge in cases. The department will intensify monitoring of Influenza-Like Illness (ILI) and Severe Acute Respiratory Infection (SARI) cases to facilitate early detection and treatment. Surveillance will also be increased at airports, railway stations and bus stands, where health teams will assess travellers showing symptoms such as fever, cough, sore throat or breathing difficulties and arrange testing and treatment when necessary. Ansari said the entire health system was being kept on alert and that the government was continuously monitoring the situation. He urged people to remain cautious, follow preventive measures and consult healthcare professionals without delay if symptoms develop. Source: ANI

Jharkhand on high alert over H1N1 as Health Minister orders hospitals to reserve beds, intensify surveillance Read More »

More Than 16,000 Ebola Vaccine Doses Arrive in Outbreak-Hit DRC

More than 16,000 doses of the Ervebo Ebola vaccine arrived in the Democratic Republic of Congo (DRC) on Friday, August 21, as the country battles its deadliest Ebola outbreak, according to an AFP journalist at the scene. A total of 16,250 doses were delivered by plane to Kinshasa, forming part of the 70,000 Ervebo doses made available to the DRC by the World Health Organisation (WHO). Of the total allocation, 20,000 doses are earmarked for a clinical trial, while 50,000 will be administered to frontline and healthcare workers. The DRC declared its 17th Ebola outbreak on May 15, although health officials believe the virus had been circulating for several weeks before the announcement. The outbreak has affected areas in the country’s north and east, where limited state presence, weak healthcare infrastructure and the presence of armed groups have complicated the response. According to the latest figures from Congolese authorities, the outbreak has resulted in 5,290 confirmed cases and 2,516 deaths. Julien Harneis, the UN’s senior Ebola coordinator, warned on Friday that the outbreak was “growing exponentially”. The Ervebo vaccine, developed by pharmaceutical company Merck, is approved for protection against the Zaire strain of Ebola but has not been approved for the Bundibugyo strain currently circulating in the DRC. WHO experts are yet to establish whether it can protect humans against the strain, although preliminary evidence, including animal studies, indicates that it may provide some level of protection. DRC Health Minister Samuel Roger Kamba said Ervebo had already been deployed during previous outbreaks, including extensively during the 2018-2020 Ebola epidemic. WHO vaccine experts this month recommended conducting a large-scale human trial to determine whether Ervebo can provide cross-protection against the Bundibugyo strain. The trial is expected to provide crucial evidence as authorities seek to contain the rapidly expanding outbreak. Researchers are also working on vaccines specifically designed to target the Bundibugyo strain. Moderna is developing an mRNA-based candidate, while another vaccine is being developed by the University of Oxford. Singapore-based Hilleman Laboratories is also set to develop an “rVSV Bundibugyo” vaccine, which WHO has described as the most promising candidate. Ebola spreads primarily through contact with infected bodily fluids and can cause severe fever and other serious symptoms. The virus has killed more than 15,000 people across Africa over the past five decades. Source: AFP  

More Than 16,000 Ebola Vaccine Doses Arrive in Outbreak-Hit DRC Read More »

Tamil Nadu to Launch Health Insurance Scheme for Elderly, Announces Major Healthcare Reforms

The Tamil Nadu government has announced a series of healthcare reforms, including a new health insurance scheme for senior citizens, annual free health check-ups for people aged 30 and above, and a major expansion of medical infrastructure and healthcare workforce. The announcements were made in the Tamil Nadu Assembly as the government outlined plans to modernise the State’s healthcare system and address emerging and future health challenges. The 87-year-old Tamil Nadu Public Health Act, 1939, will be replaced with a new comprehensive legislation designed to address contemporary healthcare requirements. The proposed law will also include a provision making unsupervised home births outside hospitals a punishable offence. The government also plans to establish ‘TN Medicity’, a world-class integrated healthcare hub bringing together clinical services, medical research, medical tourism and AYUSH facilities. An initial allocation of ₹10 crore will be made to prepare the Detailed Project Report for the proposed project. Free Annual Health Checks for People Above 30 Under the proposed ‘Nalam 360 – Annual Free Health Check-up for All’ initiative, residents aged 30 years and above will receive 14 basic health tests every year at no cost. The programme will be implemented across 1,257 government healthcare facilities in Tamil Nadu. The tests will cover key health indicators, including blood pressure, ECG, haemoglobin, complete haemogram, random blood sugar, urea, creatinine, total cholesterol, serum bilirubin, urine albumin and VIA screening. For the first time in the State, the Health Department will also introduce Home Based Diagnostic Services in metropolitan areas. The initiative will facilitate sample collection and testing at people’s homes through a public-private partnership model. New Health Policy and Institutions The government will introduce a ‘Positive Health Policy’ aimed at promoting holistic health and wellbeing at the individual, family and community levels. A ‘Nalam 360’ mobile application will accompany the initiative. Another proposed legislation, the ‘TN Institutions of State Importance in Health Care Act’, will facilitate the creation of institutions of State importance focused on delivering advanced and world-class medical services. Expansion of Healthcare Workforce To address staffing requirements, the government will create 2,500 permanent staff nurse positions. Existing nurses working on consolidated pay will also be absorbed into regular time-scale positions. In addition, 1,695 nursing posts on consolidated pay will be created at an estimated cost of ₹42.72 crore. The Medical Services Recruitment Board will recruit 3,594 medical personnel across 24 categories, including pharmacists, nursing assistants, village health nurses and ophthalmic assistants. The Health Department will also create 284 temporary super-speciality posts across 25 disciplines, including neurology, cardiology and nephrology. These positions will be placed on time-scale pay and are intended to strengthen access to specialised healthcare at the district level. The posts will also provide opportunities for doctors completing postgraduate medical education each year, particularly those posted in government hospitals under bond conditions. The government has further announced several infrastructure initiatives, including construction of new hospital buildings and procurement of additional medical equipment, as part of its broader effort to strengthen healthcare delivery across Tamil Nadu. Source: The Hindu

Tamil Nadu to Launch Health Insurance Scheme for Elderly, Announces Major Healthcare Reforms Read More »

India’s Growing Metabolic Health Crisis: Obesity, Diabetes and Hypertension

For years, India’s biggest health challenges were closely associated with infectious diseases, malnutrition and limited access to healthcare. But the country is now facing another major public-health challenge: a rapidly growing burden of metabolic and non-communicable diseases. Obesity, diabetes, hypertension and abnormal cholesterol levels are increasingly affecting Indians across age groups and income categories. What makes the situation particularly concerning is that these conditions are closely connected. A person with excess weight may develop insulin resistance, which can increase the risk of type 2 diabetes. High blood pressure and abnormal cholesterol can further increase the risk of heart disease and stroke. The problem is no longer confined to older adults. Younger Indians are increasingly exposed to sedentary lifestyles, calorie-dense diets, poor sleep and chronic stress, creating the conditions for metabolic problems much earlier in life. The World Health Organization identifies unhealthy diets, physical inactivity, tobacco use and harmful alcohol consumption as major behavioural risk factors for non-communicable diseases. These behaviours contribute to metabolic changes such as raised blood pressure, high blood glucose, overweight and obesity. The scale of India’s metabolic health problem One of the clearest pictures of India’s metabolic health comes from the ICMR-INDIAB study, a large population-based study covering adults across 31 states and Union Territories. Published in The Lancet Diabetes & Endocrinology in 2023, the study assessed more than 113,000 participants and examined the prevalence of diabetes, prediabetes, hypertension, obesity and other metabolic conditions. The findings estimated that India had around 101 million people living with diabetes, while another 136 million were in the prediabetes category. The study also highlighted substantial levels of hypertension and obesity, with considerable variation between states and between urban and rural populations. This variation is important. India does not have a single metabolic-health profile. Dietary habits, economic conditions, urbanisation, physical activity, genetics and access to healthcare differ significantly from one region to another. Yet the broader direction is clear: metabolic disorders have become a major component of India’s disease burden. Obesity is becoming a public-health issue Obesity is often discussed as an issue of appearance or weight management. Medically, however, excess body fat can have much broader consequences. India’s Ministry of Health and Family Welfare notes that overweight and obesity are important risk factors for conditions including coronary heart disease, hypertension, stroke, type 2 diabetes, fatty liver disease, certain cancers and osteoarthritis. The concern is also spreading to younger generations. In July 2026, reporting based on the World Obesity Atlas 2026 estimated that approximately 41 million children in India were overweight or obese. Around the same time, ICMR-NIN unveiled policy recommendations focused on improving children’s food environments, including measures involving food advertising, labelling, school canteens and the pricing of unhealthy foods. Childhood obesity is particularly concerning because metabolic risk can accumulate over decades. A child who develops unhealthy eating patterns and low physical activity early in life may carry those behaviours into adolescence and adulthood. That does not mean every overweight child will develop diabetes or hypertension. But it does mean that prevention has to begin much earlier than the traditional idea of starting health checks only in middle age. Diabetes: India’s expanding metabolic challenge Diabetes is perhaps the most visible part of India’s metabolic-health crisis. Type 2 diabetes develops when the body becomes resistant to insulin or does not produce enough insulin to maintain healthy blood glucose levels. Genetics can play a role, but lifestyle and environmental factors also influence risk. India’s dietary transition has become an important part of the discussion. A 2025 study based on ICMR-INDIAB data and published in Nature Medicine examined dietary patterns among more than 18,000 adults. It reported associations between higher consumption of low-quality carbohydrates, including refined grains and added sugars, and increased odds of type 2 diabetes, prediabetes and obesity. The study also found that replacing a portion of dietary carbohydrates with protein, particularly from sources such as pulses, legumes and dairy, was associated with lower diabetes risk. This does not mean that carbohydrates are inherently unhealthy or that Indians should eliminate rice or wheat from their diets. Rather, it highlights the importance of diet quality, portion sizes and dietary balance. For many Indians, the issue is not simply the presence of carbohydrates but a dietary pattern dominated by refined grains and added sugars, combined with insufficient protein, fibre, vegetables and other nutrient-dense foods. Hypertension: The silent component of the crisis If diabetes is often associated with blood-sugar testing, hypertension presents a different challenge. High blood pressure can remain undetected for years because many people experience no obvious symptoms. Persistently elevated blood pressure places additional strain on blood vessels and the heart and increases the risk of cardiovascular disease, stroke and kidney problems. India’s National Programme for Prevention and Control of Non-Communicable Diseases includes population-based screening for hypertension and diabetes among people aged 30 years and above. The screening process includes assessment of risk factors, BMI and blood pressure, among other measures. Government data also indicate the scale of the response required. The National NCD portal reported more than 9.36 crore people under treatment for hypertension and diabetes as of June 2026. Importantly, the number of people receiving treatment should not be interpreted as the total number of Indians living with these diseases. It represents people captured within the government’s treatment system. Why are metabolic diseases increasing? There is no single cause. 1. Changing food habits India’s food environment has changed rapidly. Traditional diets have increasingly been supplemented or replaced by packaged foods, sugary drinks, refined carbohydrates, fried foods and highly processed snacks. Convenience has become an important factor, particularly in urban areas where long working hours and commuting leave less time for preparing meals. 2. Physical inactivity Modern work increasingly involves sitting for prolonged periods. Office jobs, commuting, screen-based entertainment and reduced everyday physical activity can result in people expending far fewer calories than previous generations. Regular exercise cannot completely compensate for an unhealthy diet, but physical activity remains an important component of metabolic health. 3. Urbanisation Urbanisation has brought economic opportunity

India’s Growing Metabolic Health Crisis: Obesity, Diabetes and Hypertension Read More »